Home  /  Resource Library  /  Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for more than 2 Years across 4 Clinical Studies

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for more than 2 Years across 4 Clinical Studies

Retrospective study examined effectiveness and safety of duvelisib for treatment of relapsed chronic lymphoctyic leukemia.